Expression of an estrogen receptor variant lacking exon 3 in derivatives of MCF-7 cells with acquired estrogen independence or tamoxifen resistance

Journal of Molecular Endocrinology

Volumn 32, Issue 3, 2004, Pages 935-945

  Han, Feng ^a   Miksicek, Richard ^a   Clarke, Robert ^b   Conrad, Susan E ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; ESTROGEN; ESTROGEN RECEPTOR; GENE PRODUCT; TAMOXIFEN;

AMINO ACID SEQUENCE; ARTICLE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESISTANCE; DRUG RESPONSE; EXON; GENE DELETION; GENETIC ANALYSIS; GENETIC TRANSFECTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR RESISTANCE;

ANIMALS; BREAST NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ESTROGEN ANTAGONISTS; ESTROGENS; EXONS; FEMALE; GENES, REPORTER; HUMANS; PROTEIN ISOFORMS; RECEPTORS, ESTROGEN; TAMOXIFEN; TRANSFECTION;

EID: 3042777702     PISSN: 09525041     EISSN: None     Source Type: Journal    
DOI: 10.1677/jme.0.0320935     Document Type: Article

References (32)

1. Bollig A & Miksicek RJ 2000 An estrogen receptor-alpha splicing variant mediates both positive and negative effects on gene transcription. Molecular Endocrinology 14 634-649.
2. Brunner N, Boulay V, Fojo A, Freter CE, Lippman ME & Clarke R 1993a Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Research 53 283-290.
3. Brunner N, Frandsen TL, Holst-Hansen C, Bei M, Thompson EW, Wakeling AE, Lippman ME & Clarke R 1993b MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182 780. Cancer Research 53 3229-3232.
4. Clarke R, Brunner N, Katzenellenbogen BS, Thompson EW, Norman MJ, Koppi C, Paik S, Lippman ME & Dickson RB 1989 Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo. PNAS 86 3649-3653.
5. Clarke R, Leonessa F, Welch JN & Skaar TC 2001a Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacological Reviews 53 25-71.
6. Clarke R, Skaar TC, Bouker KB, Davis N, Lee YR, Welch JN & Leonessa F 2001b Molecular and pharmacological aspects of antiestrogen resistance. Journal of Steroid Biochemistry and Molecular Biology 76 71-84.
7. Daffada AA, Johnston SR, Smith IE, Detre S, King N & Dowsett M 1995 Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer. Cancer Research 55 288-293.
8. Early Breast Cancer Trialists' Collaborative Group 1992 Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 339 71-85.
9. Erenburg I, Schachter B, Mira y Lopez R & Ossowski L 1997 Loss of an estrogen receptor isoform (ER alpha delta 3) in breast cancer and the consequences of its reexpression: interference with estrogen-stimulated properties of malignant transformation. Molecular Endocrinology 11 2004-2015.
10. Fasco MJ, Keyomarsi K, Arcaro KF & Gierthy JF 2000 Expression of an estrogen receptor alpha variant protein in cell lines and tumors [In Process Citation]. Molecular and Cellular Endocrinology 162 167-180.
11. Gehm BD, McAndrews JM, Chien PY & Jameson JL 1997 Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. PNAS 94 14138-14143.
12. Gotteland M, Desauty G, Delarue JC, Liu L & May E 1995 Human estrogen receptor messenger RNA variants in both normal and tumor breast tissues. Molecular and Cellular Endocrinology 112 1-13.
13. Henderson BE, Ross R & Bernstein L 1988 Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Research 48 246-253.
14. Hopp TA & Fuqua SA 1998 Estrogen receptor variants. Journal of Mammary Gland Biology and Neoplasia 3 73-83.
15. Howell A, DeFriend D, Robertson J, Blamey R & Walton P 1995 Response to a specific antioestrogen (ICI 182,780) in tamoxifen-resistant breast cancer. Lancet 345 29-30.
16. Jiang SY, Wolf DM, Yingling JM, Chang C & Jordan VC 1992 An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol. Molecular and Cellular Endocrinology 90 77-86.
17. Jordan VC 1998 Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow. Journal of the National Cancer Institute 90 967-971.
18. Jordan VC 2000 Antiestrogens: clinical applications of pharmacology. Journal of the Society for Gynecological Investigation 7 S47-S48.
19. Koehorst SG, Jacobs HM, Thijssen JH & Blankenstein MA 1993 Wild type and alternatively spliced estrogen receptor messenger RNA in human meningioma tissue and MCF-7 breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology 45 227-233.
20. Leonessa F, Boulay V, Wright A, Thompson EW, Brunner N & Clarke R 1992 The biology of breast tumor progression. Acquisition of hormone independence and resistance to cytotoxic drugs. Acta Oncologica 31 115-123.
21. McGuire WL, Chamness GC & Fuqua SA 1992 Abnormal oestrogen receptor in clinical breast cancer. European Journal of Cancer 28 309-310.
22. Madsen MW, Reiter BE, Larsen SS, Briand P & Lykkesfeldt AE 1997 Estrogen receptor messenger RNA splice variants are not involved in antiestrogen resistance in sublines of MCF-7 human breast cancer cells. Cancer Research 57 585-589.
23. Miksicek RJ, Lei Y & Wang Y 1993 Exon skipping gives rise to alternatively spliced forms of the estrogen receptor in breast tumor cells. Breast Cancer Research and Treatment 26 163-174.
24. Milla-Santos A, Milla L, Portella J, Rallo L, Pons M, Rodes E, Casanovas J & Puig-Gali M 2003 Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study. American Journal of Clinical Oncology 26 317-322.
25. Murphy LC, Dotzlaw H, Leygue E, Coutts A & Watson P 1998 The pathophysiological role of estrogen receptor variants in human breast cancer. Journal of Steroid Biochemistry and Molecular Biology 65 175-180.
26. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL & Nicholson RI 1995 Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. Journal of the National Cancer Institute 87 746-750.
27. Pfeffer U, Fecarotta E & Vidali G 1995 Coexpression of multiple estrogen receptor variant messenger RNAs in normal and neoplastic breast tissues and in MCF-7 cells. Cancer Research 55 2158-2165.
28. Sluyser M 1994 Hormone resistance in cancer: the role of abnormal steroid receptors. Critical Reviews in Oncogenesis 5 539-554.
29. Soule HD & McGrath CM 1980 Estrogen responsive proliferation of clonal human breast carcinoma cells in athymic mice. Cancer Letters 10 177-189.
30. Thompson EW, Brunner N, Torri J, Johnson MD, Boulay V, Wright A, Lippman ME, Steeg PS & Clarke R 1993 The invasive and metastatic properties of hormone-independent but hormone-responsive variants of MCF-7 human breast cancer cells. Clinical and Experimental Metastases Exp Metastasis 11 15-26.
31. Wang Y & Miksicek RJ 1991 Identification of a dominant negative form of the human estrogen receptor. Molecular Endocrinology 5 1707-1715.
32. Wolf DM & Jordan VC 1994 The estrogen receptor from a tamoxifen-stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Research and Treatment 31 129-138.